Skip to the page

Data / Drug companies / Aphena Pharma Solutions - Tennessee, LLC

Aphena Pharma Solutions - Tennessee, LLC: 39 products in the FDA NDC directory, labeler code 53401

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Aphena Pharma Solutions - Tennessee, LLC (labeler code 53401) lists 39 products in the FDA National Drug Code Directory, covering 26 finished drugs by generic name. By type: 39 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on February 24, 2026.

The request: Watch Aphena Pharma Solutions - Tennessee, LLC (FDA labeler code 53401): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
53401
Products in commercial distribution
39
Packages
100
Finished drugs by generic name
26
Prescription products
39
Over the counter products
0
Controlled substance products
Schedule V 1
Started marketing in the last 12 months
11
Products with a marketing end date set
1
Earliest marketing start
September 30, 1990
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)39100%

Products by type

TypeProductsShare
Prescription drugs39100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet1948.7%
Tablet, film coated923.1%
Capsule410.3%
Tablet, film coated, extended release37.7%
Capsule, extended release25.1%
Tablet, coated12.6%
Capsule, delayed release12.6%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Sildenafil citrate53401-046TabletGeneric drugs (ANDA)February 24, 2026
Metoprolol tartrate53401-017TabletGeneric drugs (ANDA)February 9, 2026
Metoprolol tartrate53401-016TabletGeneric drugs (ANDA)February 9, 2026
Metoprolol tartrate53401-015TabletGeneric drugs (ANDA)February 9, 2026
Carbidopa and levodopa53401-020TabletGeneric drugs (ANDA)January 19, 2026
Metoprolol succinate53401-014Tablet, film coated, extended releaseGeneric drugs (ANDA)January 13, 2026
Metoprolol succinate53401-010Tablet, film coated, extended releaseGeneric drugs (ANDA)January 13, 2026
Metoprolol succinate53401-009Tablet, film coated, extended releaseGeneric drugs (ANDA)January 13, 2026
Allopurinol53401-025TabletGeneric drugs (ANDA)January 8, 2026
Allopurinol53401-019TabletGeneric drugs (ANDA)January 8, 2026
Pregabalin53401-007CapsuleGeneric drugs (ANDA)December 10, 2025
Naltrexone Hydrochloride53401-023Tablet, film coatedGeneric drugs (ANDA)August 15, 2025
Hydroxychloroquine sulfate53401-040TabletGeneric drugs (ANDA)May 8, 2025
Ticagrelor53401-028TabletGeneric drugs (ANDA)April 24, 2025
Trazodone Hydrochloride53401-044TabletGeneric drugs (ANDA)August 8, 2024
Trazodone Hydrochloride53401-043TabletGeneric drugs (ANDA)August 8, 2024
Metoprolol tartrate53401-012TabletGeneric drugs (ANDA)July 26, 2024
Metoprolol tartrate53401-011TabletGeneric drugs (ANDA)July 26, 2024
Varenicline53401-032Tablet, film coatedGeneric drugs (ANDA)January 30, 2023
Dexlansoprazole delayed release53401-030Capsule, delayed releaseGeneric drugs (ANDA)September 16, 2022
Carvedilol53401-045Tablet, film coatedGeneric drugs (ANDA)July 29, 2021
Terazosin53401-022CapsuleGeneric drugs (ANDA)April 30, 2021
Spironolactone53401-041Tablet, coatedGeneric drugs (ANDA)January 4, 2021
Valsartan53401-033TabletGeneric drugs (ANDA)June 23, 2020
Valsartan53401-029TabletGeneric drugs (ANDA)June 23, 2020

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.